The National Cancer Institute (NCI) awarded a $399,829 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Washington University Office of Sponsored Research Services Division in St. Louis, Missouri. The objective of this 2-year project is to validate a PET imaging approach to quantitatively measure the expression of the S1PR1 receptor in gastric tumors and correlate it with response to antibody-drug conjugate (ADC) therapies. The researchers will use molecular imaging techniques to detect changes in HER2 expression and S1PR1 levels in gastric patient-derived xenograft models in real-time, to identify biomarkers predictive of early response and resistance to ADC treatments. The goal is to establish a foundation for future clinical studies using PET imaging to predict and monitor tumor response to HER2-targeted ADC therapies in gastric cancer patients.
Generated 1/28/25, 6:59 AM